Comparing light therapy with tofacitinib for widespread vitiligo
Part of Skin clinical trials.
This study compares two treatments for widespread vitiligo: one is a combination of light therapy and a medication called Psoralen (PUVA), and the other is a pill called Tofacitinib (a JAK inhibitor) that may help restore skin color. The goal is to see which treatment works better and is safer for adults with stable vitiligo affecting a large area of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- Your vitiligo patches cover more than 10% of your body (about the size of 10 of your palms).
- Your vitiligo has been stable for the last 3 months, with no new patches or growth.
- You are not allergic to Psoralen, Tofacitinib, or sunlight.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with active generalized vitiligo covering more than 5% of their body (not counting hands and feet). It also looks at a protein in the blood called s100B to see how it relates to the condition and treatment response.
This study compares two treatments for vitiligo: narrowband UVB light therapy combined with either tacrolimus ointment or calcipotriol ointment. It aims to see which combination works better and is safer for people with stable, limited vitiligo.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
This study compares two medications, methotrexate and tofacitinib, to see which works better for chronic plaque psoriasis in adults with moderate to severe symptoms. If you've tried creams that didn't help enough, you may be eligible.
This trial tests whether adding a type of light therapy (narrow-band UVB) to a daily pill called ritlecitinib works better than the pill alone for treating vitiligo. It may help if you have non-segmental vitiligo covering a moderate amount of skin.
This study tests an experimental medication (ACT-777991) taken by mouth to see if it can help repigment skin in adults with non-segmental vitiligo. It aims to learn how safe it is and how well it works.
Hear when a new Vitiligo, Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.